STriTuVaD: In Silico Trial for Tuberculosis Vaccine Development
INFECTIOUS DISEASE RESEARCH INSTITUTE
participó en un
H2020:
H2020-SC1-2016-2017
Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected wi...
2017-11-13 - 2023-01-31 | Financiado
2017-11-13 - 2023-01-31 | Financiado
ADITEC: Advanced Immunization Technologies
INFECTIOUS DISEASE RESEARCH INSTITUTE
participó en un
FP7:
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious...
Financiado
Financiado
MULEVACLIN: Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis
INFECTIOUS DISEASE RESEARCH INSTITUTE
participó en un
FP7:
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the b...
Financiado
Financiado
* No se disponen de datos de la empresa actual.